title: Biochemical and pharmacological characterization of the serotonin transporter in human peripheral blood lymphocytes.
abstract: The serotonin transporter (5-HTT) plays a critical role in the termination of serotonin neurotransmission and represents the prime target for selective serotonin reuptake inhibitors (SSRIs). In the present study, the 5-HTT protein in human peripheral blood lymphocyte was characterized pharmacologically and biochemically. The tricyclic antidepressant drug [(3)H]imipramine, an established ligand for the neuronal and platelet 5-HTT, bound saturably and reversibly to a single population of non-interacting binding sites in fresh human peripheral blood lymphocytes. The affinity of [(3)H]imipramine (K(d)) to the transporter, calculated from association and dissociation kinetic experiments, was similar to that obtained from the equilibrium study. The function of the transporter was studied using high affinity [(3)H]5-HT uptake into fresh lymphocytes. [(3)H]Imipramine binding and [(3)H]5-HT uptake were inhibited by tricyclic antidepressants as well as by SSRIs. Western blot analysis as well as immunoprecipitation analysis revealed labeling of a single protein band of approximately 100 kDa. The presence of the 5-HTT in easily accessible nucleated cells such as peripheral blood lymphocytes might permit molecular genetic studies in mood and anxiety disorder patients, and might enhance the understanding of the different efficacies of antidepressants in depressed patients.
authors.affiliation: Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors.forename: Tal
authors.initials: T
authors.lastname: Barkan
authors.forename: David
authors.initials: D
authors.lastname: Gurwitz
authors.forename: Galit
authors.initials: G
authors.lastname: Levy
authors.forename: Abraham
authors.initials: A
authors.lastname: Weizman
authors.forename: Moshe
authors.initials: M
authors.lastname: Rehavi
mesh_terms: D000929:Antidepressive Agents, Tricyclic / Q000494:pharmacology; D001665:Binding Sites / Q000187:drug effects; D015153:Blotting, Western / Q000379:methods; D002352:Carrier Proteins / Q000187:drug effects / Q000378:metabolism* / Q000502:physiology; D003164:Competitive Bidding / Q000379:methods; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007099:Imipramine / Q000494:pharmacology; D020128:Inhibitory Concentration 50; D008214:Lymphocytes / Q000187:drug effects / Q000378:metabolism*; D008562:Membrane Glycoproteins / Q000187:drug effects / Q000378:metabolism* / Q000502:physiology; D026901:Membrane Transport Proteins; D009419:Nerve Tissue Proteins / Q000187:drug effects / Q000378:metabolism* / Q000502:physiology; D011233:Precipitin Tests / Q000379:methods; D012701:Serotonin / Q000378:metabolism; D050486:Serotonin Plasma Membrane Transport Proteins; D014316:Tritium
chemical_list: D000929:Antidepressive Agents, Tricyclic; D002352:Carrier Proteins; D008562:Membrane Glycoproteins; D026901:Membrane Transport Proteins; D009419:Nerve Tissue Proteins; C493230:SLC6A4 protein, human; D050486:Serotonin Plasma Membrane Transport Proteins; D014316:Tritium; D012701:Serotonin; D007099:Imipramine